China
Hong Kong SAR ChinaBiotech & Genomic Medicine▲
3SBio Signs MindRank AI Deal to Commercialize Oral GLP-1 Obesity Drug MDR-001
3SBio subsidiaries Zhejiang Sunshine Mandi and Zhejiang Wansheng have signed an agreement with MindRank AI to commercialize MDR-001, an oral GLP-1 candidate in Phase 3 obesity trials. The deal lands as 3SBio shares trade at HK$15.07, with a 1-year total shareholder return down 45.58 percent, a 30-day share price return down 6.69 percent and a year-to-date share price return down 38.69 percent, even as the 3-year total shareholder return is up more than 2x. On valuation, 3SBio trades at a P/E of 3.9x against a Hong Kong Biotechs industry average of 17.3x and a peer group average of 36.2x, with an estimated fair P/E of 8.2x. A discounted cash flow model puts 3SBio's estimated future cash flow value at HK$33.62 versus the current HK$15.07 share price. Recent declines in revenue and net income, combined with the weak 1-year return, could pressure sentiment if MDR-001 progress disappoints.
About megatrends
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Technology
Longevity & Life Extension › GLP-1 Healthspan Proxies Technology
1530.HK · Demand · Positive 3SBio subsidiaries signed a deal with MindRank AI to commercialize the Phase 3 oral GLP-1 obesity candidate MDR-001, expanding its obesity drug pipeline.
MindRank AI Ltd · Demand · Positive MindRank AI signed the agreement with 3SBio to commercialize its oral GLP-1 candidate MDR-001.
603010.CG · Demand · Positive Zhejiang Wansheng is named as a 3SBio subsidiary signing the agreement to commercialize MDR-001.
Zhejiang Sansheng Wandi Pharmaceutical · Demand · Positive Zhejiang Sunshine Mandi is named as a 3SBio subsidiary signing the agreement to commercialize MDR-001.